Show simple item record

dc.contributor.authorGupta, Vikas
dc.contributor.authorKim, Soyoung
dc.contributor.authorHu, Zhen-Huan
dc.contributor.authorLiu, Ying
dc.contributor.authorAljurf, Mahmoud
dc.contributor.authorBacher, Ulrike
dc.contributor.authorBeitinjaneh, Amer
dc.contributor.authorCahn, Jean-Yves
dc.contributor.authorCerny, Jan
dc.contributor.authorCopelan, Edward
dc.contributor.authorGadalla, Shahinaz M
dc.contributor.authorGale, Robert Peter
dc.contributor.authorGanguly, Siddhartha
dc.contributor.authorGeorge, Biju
dc.contributor.authorGerds, Aaron T
dc.contributor.authorGergis, Usama
dc.contributor.authorHamilton, Betty K
dc.contributor.authorHashmi, Shahrukh
dc.contributor.authorHildebrandt, Gerhard C
dc.contributor.authorKamble, Rammurti T
dc.contributor.authorKindwall-Keller, Tamila
dc.contributor.authorLazarus, Hillard M
dc.contributor.authorLiesveld, Jane L
dc.contributor.authorLitzow, Mark
dc.contributor.authorMaziarz, Richard T
dc.contributor.authorNishihori, Taiga
dc.contributor.authorOlsson, Richard F
dc.contributor.authorRizzieri, David
dc.contributor.authorSavani, Bipin N
dc.contributor.authorSeo, Sachiko
dc.contributor.authorSolh, Melhem
dc.contributor.authorSzer, Jeff
dc.contributor.authorVerdonck, Leo F
dc.contributor.authorWirk, Baldeep
dc.contributor.authorWoolfrey, Ann
dc.contributor.authorYared, Jean A
dc.contributor.authorAlyea, Edwin P
dc.contributor.authorPopat, Uday R
dc.contributor.authorSobecks, Ronald M
dc.contributor.authorScott, Bart L
dc.contributor.authorNakamura, Ryotaro
dc.contributor.authorSaber, Wael
dc.date.accessioned2020-10-20T13:51:49Z
dc.date.available2020-10-20T13:51:49Z
dc.date.issued2020-10-13
dc.identifier.urihttp://hdl.handle.net/10713/13905
dc.description.abstractComparative outcomes of allogeneic hematopoietic cell transplantation (HCT) for BCR-ABL12 myeloproliferative neoplasms (MPNs) in blast phase (MPN-BP) vs de novo acute myeloid leukemia (AML), and AML with prior myelodysplastic syndromes (MDSs; post-MDS AML), are unknown. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we compared HCT outcomes in 177 MPN-BP patients with 4749 patients with de novo AML, and 1104 patients with post-MDS AML, using multivariate regression analysis in 2 separate comparisons. In a multivariate Cox model, no difference in overall survival (OS) or relapse was observed in patients with MPN-BP vs de novo AML with active leukemia at HCT. Patients with MPN-BP in remission had inferior OS in comparison with de novo AML in remission (hazard ratio [HR], 1.40 [95% confidence interval [CI], 1.12-1.76]) due to higher relapse rate (HR, 2.18 [95% CI, 1.69-2.80]). MPN-BP patients had inferior OS (HR, 1.19 [95% CI, 1.00-1.43]) and increased relapse (HR, 1.60 [95% CI, 1.31-1.96]) compared with post-MDS AML. Poor-risk cytogenetics were associated with increased relapse in both comparisons. Peripheral blood grafts were associated with decreased relapse in MPN-BP and post-MDS AML (HR, 0.70 [95% CI, 0.57-0.86]). Nonrelapse mortality (NRM) was similar between MPN-BP vs de novo AML, and MPN-BP vs post-MDS AML. Total-body irradiation-based myeloablative conditioning was associated with higher NRM in both comparisons. Survival of MPN-BP after HCT is inferior to de novo AML in remission and post-MDS AML due to increased relapse. Relapse-prevention strategies are required to optimize HCT outcomes in MPN-BP.en_US
dc.description.sponsorshipThe CIBMTR was supported primarily by Public Health Service U24CA076518 from the National Cancer Institute, the National Heart, Lung, and Blood Institute, and the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U24HL138660 from the National Heart, Lung, and Blood Institute and National Cancer Institute; T3HL147741, R21HL140314, and U01HL128568 from the National Heart, Lung, and Blood Institute; HHSH250201700006C, SC1MC31881-01-00, and HHSH250201700007C from the Health Resources and Services Administration; and N00014-18-1-2850, N00014-18-1-2888, and N00014-20-1-2705 from the Office of Naval Research. Additional federal support was provided by P01CA111412, R01CA152108, R01CA215134, R01CA218285, and R01CA231141 from the National Cancer Institute; R01HL126589 from the National Heart, Lung, and Blood Institute; R01AI128775 from the National Institute of Allergy and Infectious Diseases; R01HL129472, R01HL130388, and R01HL131731 from the National Heart, Lung, and Blood Institute; U01AI069197 and U01AI126612 from the National Institute of Allergy and Infectious Diseases; and Biomedical Advanced Research and Development Authority.en_US
dc.description.urihttps://doi.org/10.1182/bloodadvances.2020002621en_US
dc.language.isoenen_US
dc.publisherAmerican Society of Hematologyen_US
dc.relation.ispartofBlood advancesen_US
dc.subjectclinical trials and observationsen_US
dc.subject.meshTransplantationen_US
dc.titleComparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDSen_US
dc.typeArticleen_US
dc.identifier.doi10.1182/bloodadvances.2020002621
dc.identifier.pmid33007075
dc.source.volume4
dc.source.issue19
dc.source.beginpage4748
dc.source.endpage4757
dc.source.countryUnited States


This item appears in the following Collection(s)

Show simple item record